HPV vaccination recommendation practices among adolescent health care providers in 5 countries

dc.contributor.authorTopazian, Hillary M.
dc.contributor.authorKundu, Debanjali
dc.contributor.authorPeebles, Kathryn
dc.contributor.authorRamos, Silvina
dc.contributor.authorMorgan, Karen
dc.contributor.authorKim, Chan Joo
dc.contributor.authorRichter, Karin Louise
dc.contributor.authorBrewer, Noel T.
dc.contributor.authorPeris, Mercè
dc.contributor.authorSmith, Jennifer S.
dc.date.accessioned2018-10-01T09:18:45Z
dc.date.issued2018-12
dc.description.abstractSTUDY OBJECTIVE : To assess adolescent health care providers’ recommendations for, and attitudes towards human papillomavirus (HPV) vaccination in 5 countries. DESIGN : In-depth interviews of adolescent health care providers, 2013-2014. SETTING : Five countries where HPV vaccination is at various stages of implementation into national programs: Argentina, Malaysia, South Africa, South Korea, and Spain. PARTICIPANTS : Adolescent health care providers (N = 151) who had administered or overseen provision of adolescent vaccinations (N = Argentina: 30, Malaysia: 30, South Africa: 31, South Korea: 30, Spain: 30). MAIN OUTCOME MEASURES : Frequency of HPV vaccination recommendation, reasons providers do not always recommend the vaccine and facilitators to doing so, comfort level with recommending the vaccine, reasons for any discomfort, and positive and negative aspects of HPV vaccination. RESULTS : Over half of providers 82/151 (54%) recommend HPV vaccination always or most of the time (range: 20% in Malaysia to 90% in Argentina). Most providers 112/151 (74%) said they were comfortable recommending HPV vaccination, although South Korea was an outlier 10/30 (33%). Providers cited protection against cervical cancer 124/151 (83%) and genital warts 56/151 (37%) as benefits of HPV vaccination. When asked about the problems with HPV vaccination, providers mentioned high cost 75/151 (50% overall; range: 26% in South Africa to 77% in South Korea) and vaccination safety 28/151 (19%; range: 7% in South Africa to 33% in Spain). Free, low-cost, or publicly available vaccination 59/151 (39%), and additional data on vaccination safety 52/151 (34%) and efficacy 43/151 (28%) were the most commonly cited facilitators of health provider vaccination recommendation. CONCLUSION : Interventions to increase HPV vaccination should consider a country's specific provider concerns, such as reducing cost and providing information on vaccination safety and efficacy.en_ZA
dc.description.departmentMedical Virologyen_ZA
dc.description.embargo2019-12-01
dc.description.librarianhj2018en_ZA
dc.description.sponsorshipThis study was an ancillary study to the GlaxoSmithKline Biologicals SA -funded parent study (ID: 117339 ), which aimed to compare 2- vs 3-dose HPV vaccination. GSK was not involved in the conduct and analysis of this ancillary study. Hillary M. Topazian was supported by the UNC's Graduate School Doctoral Merit Assistantship for study in Epidemiology during the completion of this work.en_ZA
dc.description.urihttps://www.journals.elsevier.com/journal-of-pediatric-and-adolescent-gynecologyen_ZA
dc.identifier.citationTopazian, H.M., Kundu, D., Peebles, K. et al. 2018, 'HPV vaccination recommendation practices among adolescent health care providers in 5 countries', Journal of Pediatric and Adolescent Gynecology, vol. 31, no. 6, pp. 575-582.e2.en_ZA
dc.identifier.issn1083-3188 (print)
dc.identifier.issn1873-4332 (online)
dc.identifier.other10.1016/j.jpag.2018.06.010
dc.identifier.urihttp://hdl.handle.net/2263/66670
dc.language.isoenen_ZA
dc.publisherElsevieren_ZA
dc.rights© 2018 North American Society for Pediatric and Adolescent Gynecology. Published by Elsevier Inc. Notice : this is the author’s version of a work that was accepted for publication in Journal of Pediatric and Adolescent Gynecology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. A definitive version was subsequently published in Journal of Pediatric and Adolescent Gynecology, vol. 31, no. 6, pp. 575-582.e2, 2018. doi : 10.1016/j.jpag.2018.06.010.en_ZA
dc.subjectHuman papillomavirus (HPV)en_ZA
dc.subjectHPV-associated cancersen_ZA
dc.subjectCervical canceren_ZA
dc.subjectVaccinationen_ZA
dc.subjectHealth care provider recommendationen_ZA
dc.titleHPV vaccination recommendation practices among adolescent health care providers in 5 countriesen_ZA
dc.typePostprint Articleen_ZA

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Topazian_HPV_2018.pdf
Size:
2.18 MB
Format:
Adobe Portable Document Format
Description:
Postprint Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description: